Similarly, in contrast to a mortality of at least 75% in mice bearing a different tumor, NS-1 myeloma, all mice inoculated with myeloma and treated with the benzyl derivative of vitalethine (100 pg/kg) exhibited long-term survival.
These rather good, lifetime responses in mice were obtained even though the regimens used have not yet been optimized. In addition to these carefully controlled studies in laboratory animals, desirable responses have also been obtained in the outpatient treatments of three out of four dogs and two horses (all suffering from spontaneous recurrent melanoma) using vitalethine or its benzyl derivative, three of which are still being monitored.
GO TO:
Home | Overview | People | Journal | Nutrition |
Environment |
|
WWW Links | Outline | e-mail us |